The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies
- 5 September 2001
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 20 (19) , 2827-2843
Abstract
The continual reassessment method (CRM) provides a Bayesian estimation of the maximum tolerated dose (MTD) in phase I clinical trials and is also used to estimate the minimal efficacy dose (MED) in phase II clinical trials. In this paper we propose Bayesian stopping rules for the CRM, based on either posterior or predictive probability distributions that can be applied sequentially during the trial. These rules aim at early detection of either the mis‐choice of dose range or a prefixed gain in the point estimate or accuracy of estimated probability of response associated with the MTD (or MED). They were compared through a simulation study under six situations that could represent the underlying unknown dose–response (either toxicity or failure) relationship, in terms of sample size, probability of correct selection and bias of the response probability associated to the MTD (or MED). Our results show that the stopping rules act correctly, with early stopping by using the two first rules based on the posterior distribution when the actual underlying dose–response relationship is far from that initially supposed, while the rules based on predictive gain functions provide a discontinuation of inclusions whatever the actual dose–response curve after 20 patients on average, that is, depending mostly on the accumulated data. The stopping rules were then applied to a data set from a dose‐ranging phase II clinical trial aiming at estimating the MED dose of midazolam in the sedation of infants during cardiac catheterization. All these findings suggest the early use of the two first rules to detect a mis‐choice of dose range, while they confirm the requirement of including at least 20 patients at the same dose to reach an accurate estimate of MTD (MED). A two‐stage design is under study. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- Miscellanea. A stopping rule for the continual reassessment methodBiometrika, 1998
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- AN EXTENSION OF THE CONTINUAL REASSESSMENT METHODS USING A PRELIMINARY UP‐AND‐DOWN DESIGN IN A DOSE FINDING STUDY IN CANCER PATIENTS, IN ORDER TO INVESTIGATE A GREATER RANGE OF DOSESStatistics in Medicine, 1995
- BAYESIAN DECISION PROCEDURES FOR DOSE DETERMINING EXPERIMENTSStatistics in Medicine, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993
- Bayesian methods for phase I clinical trialsStatistics in Medicine, 1992
- Methods for dose finding studies in cancer clinical trials: A review and results of a monte carlo studyStatistics in Medicine, 1991
- Sensitivity of Bayes Inference with Data-Dependent Stopping RulesThe American Statistician, 1984
- Design of Phase I and II Clinical Trials in Cancer: A Statistician's ViewCancer Investigation, 1984